{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:44:49Z","timestamp":1790138689793,"version":"4.0.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["POSTD20024DEBA"],"award-info":[{"award-number":["POSTD20024DEBA"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RYC2021-031197-I"],"award-info":[{"award-number":["RYC2021-031197-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["MICINN, EUR2019-103835"],"award-info":[{"award-number":["MICINN, EUR2019-103835"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS\/07R\/2022"],"award-info":[{"award-number":["DJCLS\/07R\/2022"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS\/07R\/2022"],"award-info":[{"award-number":["DJCLS\/07R\/2022"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS\/07R\/2022"],"award-info":[{"award-number":["DJCLS\/07R\/2022"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PRE2018-083183"],"award-info":[{"award-number":["PRE2018-083183"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fight Kids Cancer Funding Programme","award":["Cure2MLL"],"award-info":[{"award-number":["Cure2MLL"]}]},{"name":"Fight Kids Cancer Funding Programme","award":["Cure2MLL"],"award-info":[{"award-number":["Cure2MLL"]}]},{"name":"Fight Kids Cancer Funding Programme","award":["Cure2MLL"],"award-info":[{"award-number":["Cure2MLL"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00822"],"award-info":[{"award-number":["PI20\/00822"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01451"],"award-info":[{"award-number":["PI21\/01451"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Infants diagnosed with B cell acute lymphoblastic leukemia (B-ALL) and t(4;11) chromosomal rearrangement display poor therapeutic response, associated to the low expression of B lymphocyte factor HDAC7. This study was conceived to identify a therapeutic strategy for t(4;11) B-ALL that restores optimal HDAC7 expression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A multiomics approach in a large infant pro-B-ALL cohort was employed to identify HDAC7\u2019s repression mechanism. These data, combined with cell culture assays in a variety of pro-B-ALL cell lines with differential HDAC7 levels, led us to define a novel combination therapy. Murine leukemia models and ex vivo assays using patient-derived xenografts (PDX) were employed to assess the benefits of this therapy when incorporated to glucocorticoid-based chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our data demonstrates that HDAC7 is epigenetically silenced by EZH2 and KMT2A::AFF1 fusion protein. Remarkably, the Menin-1 inhibitor MI-538 restores HDAC7 expression, and the effect is enhanced by class I HDAC inhibitor chidamide. This treatment drives leukemic pro-B cells towards a more differentiated state and impairs aberrant proliferation in an HDAC7-dependent manner. This newly identified therapy increases glucocorticoid sensitivity of PDX cells ex vivo, by repressing RUNX2 transcription factor. Finally, combining MI-538 and chidamide with standard chemotherapy reduces PDX cells engraftment in vivo and delays relapse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The combined therapy proposed, based on Menin-1 inhibition, improves t(4;11) B-ALL cells\u2019 response to standard therapy, an effect partially mediated by HDAC7 induction. Therefore, this novel therapy opens a new field for personalized treatments in high-risk leukemia, especially for infants presenting low expression of HDAC7 B cell factor.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40364-025-00810-1","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:51:44Z","timestamp":1753707104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"13","author":[{"given":"Oriol","family":"de Barrios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Oc\u00f3n-Gabarr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Gusi-Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Collazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Meler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola A.","family":"Romec\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Mart\u00ednez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ram\u00f3n","family":"Tejedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario F.","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Bardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Marschalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"810_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc1816","volume":"6","author":"M Greaves","year":"2006","unstructured":"Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6:193\u2013203.","journal-title":"Nat Rev Cancer"},{"key":"810_CR2","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1182\/blood-2015-09-667378","volume":"126","author":"A Sanjuan-Pla","year":"2015","unstructured":"Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam RW, Marschalek R, et al. Revisiting the biology of infant t(4;11)\/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood. 2015;126:2676\u201385.","journal-title":"Blood"},{"key":"810_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","volume":"50","author":"C-H Pui","year":"2013","unstructured":"Pui C-H, Evans WE. A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia. Semin Hematol. 2013;50:185\u201396.","journal-title":"Semin Hematol"},{"key":"810_CR4","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gr\u00f6ger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988\u20131005.","journal-title":"Leukemia"},{"key":"810_CR5","doi-asserted-by":"crossref","unstructured":"Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. Longo DL, editor. N Engl J Med. 2015;373:1541\u201352.","DOI":"10.1056\/NEJMra1400972"},{"key":"810_CR6","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.19.00261","volume":"37","author":"R Pieters","year":"2019","unstructured":"Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019;37:2246\u201356.","journal-title":"J Clin Oncol"},{"key":"810_CR7","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM van der Sluis","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. N Engl J Med. 2023;388:1572\u201381.","journal-title":"N Engl J Med"},{"key":"810_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.leu.2404578","volume":"21","author":"MWJC Jansen","year":"2007","unstructured":"Jansen MWJC, Corral L, van der Velden VHJ, Panzer-Gr\u00fcmayer R, Schrappe M, Schrauder A, et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia. 2007;21:633\u201341.","journal-title":"Leukemia"},{"key":"810_CR9","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.celrep.2014.04.015","volume":"7","author":"BP Mishra","year":"2014","unstructured":"Mishra BP, Zaffuto KM, Artinger EL, Org T, Mikkola HKA, Cheng C, et al. The Histone Methyltransferase Activity of MLL1 Is Dispensable for Hematopoiesis and Leukemogenesis. Cell Rep. 2014;7:1239\u201347.","journal-title":"Cell Rep"},{"key":"810_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2020.194548","volume":"1863","author":"S Takahashi","year":"2020","unstructured":"Takahashi S, Yokoyama A. The molecular functions of common and atypical MLL fusion protein complexes. Biochim Biophys Acta - Gene Regul Mech. 2020;1863: 194548.","journal-title":"Biochim Biophys Acta - Gene Regul Mech"},{"key":"810_CR11","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1038\/s41467-023-40981-9","volume":"14","author":"NT Crump","year":"2023","unstructured":"Crump NT, Smith AL, Godfrey L, Dopico-Fernandez AM, Denny N, Harman JR, et al. MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia. Nat Commun. 2023;14:5208.","journal-title":"Nat Commun"},{"key":"810_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.molcel.2010.05.011","volume":"38","author":"TA Milne","year":"2010","unstructured":"Milne TA, Kim J, Wang GG, Stadler SC, Basrur V, Whitcomb SJ, et al. Multiple Interactions Recruit MLL1 and MLL1 Fusion Proteins to the HOXA9 Locus in Leukemogenesis. Mol Cell. 2010;38:853\u201363.","journal-title":"Mol Cell"},{"key":"810_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bcp.2017.09.007","volume":"147","author":"D Steinhilber","year":"2018","unstructured":"Steinhilber D, Marschalek R. How to effectively treat acute leukemia patients bearing MLL-rearrangements? Biochem Pharmacol. 2018;147:183\u201390.","journal-title":"Biochem Pharmacol"},{"key":"810_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama A, Somervaille TCP, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis. Cell. 2005;123:207\u201318.","journal-title":"Cell"},{"key":"810_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","volume":"19","author":"JH Bushweller","year":"2019","unstructured":"Bushweller JH. Targeting transcription factors in cancer \u2014 from undruggable to reality. Nat Rev Cancer. 2019;19:611\u201324.","journal-title":"Nat Rev Cancer"},{"key":"810_CR16","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1021\/acs.jmedchem.5b01305","volume":"59","author":"D Borkin","year":"2016","unstructured":"Borkin D, Pollock J, Kempinska K, Purohit T, Li X, Wen B, et al. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). J Med Chem. 2016;59:892\u2013913.","journal-title":"J Med Chem"},{"key":"810_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-018-0015-6","volume":"18","author":"M Greaves","year":"2018","unstructured":"Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2018;18:471\u201384.","journal-title":"Nat Rev Cancer"},{"key":"810_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0092-8674(00)80955-1","volume":"96","author":"LH Glimcher","year":"1999","unstructured":"Glimcher LH, Singh H. Transcription Factors in Lymphocyte Development\u2014 T and B Cells Get Together. Cell. 1999;96:13\u201323.","journal-title":"Cell"},{"key":"810_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.it.2009.03.008","volume":"30","author":"H Schmidlin","year":"2009","unstructured":"Schmidlin H, Diehl SA, Blom B. New insights into the regulation of human B-cell differentiation. Trends Immunol. 2009;30:277\u201385.","journal-title":"Trends Immunol"},{"key":"810_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4161\/epi.4.7.10052","volume":"4","author":"M Parra","year":"2009","unstructured":"Parra M. Epigenetic events during B lymphocyte development. Epigenetics. 2009;4:462\u20138.","journal-title":"Epigenetics [Internet]"},{"key":"810_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1182\/blood-2014-12-575688","volume":"126","author":"R Somasundaram","year":"2015","unstructured":"Somasundaram R, Prasad MAJ, Ungerb\u00e4ck J, Sigvardsson M. Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia. Blood. 2015;126:144\u201352.","journal-title":"Blood"},{"key":"810_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/2643-3230.BCD-20-0011","volume":"1","author":"U Fischer","year":"2020","unstructured":"Fischer U, Yang JJ, Ikawa T, Hein D, Vicente-Due\u00f1as C, Borkhardt A, et al. Cell Fate Decisions: The Role of Transcription Factors in Early B-cell Development and Leukemia. Blood Cancer Discov. 2020;1:224\u201333.","journal-title":"Blood Cancer Discov"},{"key":"810_CR23","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1084\/jem.20150821","volume":"213","author":"A Azagra","year":"2016","unstructured":"Azagra A, Rom\u00e1n-Gonz\u00e1lez L, Collazo O, Rodr\u00edguez-Ubreva J, de Y\u00e9benes VG, Barneda-Zahonero B, et al. In vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development. J Exp Med. 2016;213:2591\u2013601.","journal-title":"J Exp Med"},{"key":"810_CR24","doi-asserted-by":"publisher","first-page":"8471","DOI":"10.1093\/nar\/gkac619","volume":"50","author":"A Azagra","year":"2022","unstructured":"Azagra A, Meler A, de Barrios O, Tom\u00e1s-Daza L, Collazo O, Monterde B, et al. The HDAC7\u2013TET2 epigenetic axis is essential during early B lymphocyte development. Nucleic Acids Res. 2022;50:8471\u201390.","journal-title":"Nucleic Acids Res"},{"key":"810_CR25","doi-asserted-by":"crossref","unstructured":"Barneda-Zahonero B, Collazo O, Azagra A, Fern\u00e1ndez-Duran I, Serra-Musach J, Islam ABMMK, et al. The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma. Cell Death Dis. 2015;6:e1635.","DOI":"10.1038\/cddis.2014.594"},{"key":"810_CR26","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s41375-020-01097-x","volume":"35","author":"O de Barrios","year":"2021","unstructured":"de Barrios O, Galaras A, Trincado JL, Azagra A, Collazo O, Meler A, et al. HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia. Leukemia. 2021;35:2086\u201391.","journal-title":"Leukemia"},{"key":"810_CR27","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3324\/haematol.2018.206375","volume":"104","author":"A Agraz-Doblas","year":"2019","unstructured":"Agraz-Doblas A, Bueno C, Bashford-Rogers R, Roy A, Schneider P, Bardini M, et al. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. Haematologica. 2019;104:1176\u201388.","journal-title":"Haematologica"},{"key":"810_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.mrfmmm.2008.08.006","volume":"647","author":"S Gopalakrishnan","year":"2008","unstructured":"Gopalakrishnan S, Van Emburgh BO, Robertson KD. DNA methylation in development and human disease. Mutat Res Mol Mech Mutagen. 2008;647:30\u20138.","journal-title":"Mutat Res Mol Mech Mutagen"},{"key":"810_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/ng0210-100","volume":"42","author":"E Martinez-Garcia","year":"2010","unstructured":"Martinez-Garcia E, Licht JD. Deregulation of H3K27 methylation in cancer. Nat Genet. 2010;42:100\u20131.","journal-title":"Nat Genet"},{"key":"810_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med. 2016;22:128\u201334.","journal-title":"Nat Med"},{"key":"810_CR31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1101\/gad.191163.112","volume":"26","author":"H Hock","year":"2012","unstructured":"Hock H. A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev. 2012;26:751\u20135.","journal-title":"Genes Dev"},{"key":"810_CR32","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","volume":"13","author":"JM Benito","year":"2015","unstructured":"Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, et al. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015;13:2715\u201327.","journal-title":"Cell Rep"},{"key":"810_CR33","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/2159-8290.CD-12-0208","volume":"2","author":"H Geng","year":"2012","unstructured":"Geng H, Brennan S, Milne TA, Chen W-Y, Li Y, Hurtz C, et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2012;2:1004\u201323.","journal-title":"Cancer Discov"},{"key":"810_CR34","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.celrep.2016.12.054","volume":"18","author":"J Kerry","year":"2017","unstructured":"Kerry J, Godfrey L, Repapi E, Tapia M, Blackledge NP, Ma H, et al. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. Cell Rep. 2017;18:482\u201395.","journal-title":"Cell Rep"},{"key":"810_CR35","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/sj.onc.1210774","volume":"27","author":"M Nuytten","year":"2008","unstructured":"Nuytten M, Beke L, Van Eynde A, Ceulemans H, Beullens M, Van Hummelen P, et al. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing. Oncogene. 2008;27:1449\u201360.","journal-title":"Oncogene"},{"key":"810_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","volume":"18","author":"C Lu","year":"2010","unstructured":"Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of Tumor Angiogenesis by EZH2. Cancer Cell. 2010;18:185\u201397.","journal-title":"Cancer Cell"},{"key":"810_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:104.","journal-title":"J Hematol Oncol"},{"key":"810_CR38","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2018-04-845628","volume":"132","author":"J Zhang","year":"2018","unstructured":"Zhang J, Zhang Y, Zhang M, Liu C, Liu X, Yin J, et al. FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia. Blood. 2018;132:2520\u20134.","journal-title":"Blood"},{"key":"810_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2014.39","volume":"3","author":"K Ahmad","year":"2014","unstructured":"Ahmad K, Katryniok C, Scholz B, Merkens J, L\u00f6scher D, Marschalek R, et al. Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL. Oncogenesis. 2014;3: e127.","journal-title":"Oncogenesis"},{"key":"810_CR40","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0092-8674(94)90077-9","volume":"79","author":"G Bain","year":"1994","unstructured":"Bain G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, Weintraub BC, et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell. 1994;79:885\u201392.","journal-title":"Cell"},{"key":"810_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nri3570","volume":"14","author":"MR Clark","year":"2014","unstructured":"Clark MR, Mandal M, Ochiai K, Singh H. Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. Nat Rev Immunol. 2014;14:69\u201380.","journal-title":"Nat Rev Immunol"},{"key":"810_CR42","doi-asserted-by":"crossref","unstructured":"Otero DC, Rickert RC. CD19 function in early and late B cell development. II. CD19 facilitates the pro-B\/pre-B transition. J Immunol. 2003;171:5921\u201330.","DOI":"10.4049\/jimmunol.171.11.5921"},{"key":"810_CR43","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1182\/blood-2017-02-766204","volume":"129","author":"KA Kruth","year":"2017","unstructured":"Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, Yang H, et al. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood. 2017;129:3000\u20138.","journal-title":"Blood"},{"key":"810_CR44","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.celrep.2015.03.019","volume":"11","author":"D Grote","year":"2015","unstructured":"Grote D, Moison C, Duhamel S, Chagraoui J, Girard S, Yang J, et al. E4F1 Is a Master Regulator of CHK1-Mediated Functions. Cell Rep. 2015;11:210\u20139.","journal-title":"Cell Rep"},{"key":"810_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00018-010-0530-4","volume":"68","author":"JD Stumpf","year":"2011","unstructured":"Stumpf JD, Copeland WC. Mitochondrial DNA replication and disease: insights from DNA polymerase \u03b3 mutations. Cell Mol Life Sci. 2011;68:219\u201333.","journal-title":"Cell Mol Life Sci"},{"key":"810_CR46","first-page":"7417","volume":"61","author":"X Wang","year":"2001","unstructured":"Wang X, Wang L, Callister MD, Putnam JB, Mao L, Li L. Human Rad17 is phosphorylated upon DNA damage and also overexpressed in primary non-small cell lung cancer tissues. Cancer Res. 2001;61:7417\u201321.","journal-title":"Cancer Res"},{"key":"810_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.998388","volume":"12","author":"L Carlsen","year":"2022","unstructured":"Carlsen L, El-Deiry WS. Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation. Front Oncol. 2022;12: 998388.","journal-title":"Front Oncol"},{"key":"810_CR48","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.3390\/ijms24087001","volume":"24","author":"T-C Lin","year":"2023","unstructured":"Lin T-C. RUNX2 and Cancer. Int J Mol Sci. 2023;24:7001.","journal-title":"Int J Mol Sci"},{"key":"810_CR49","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1038\/onc.2008.195","volume":"27","author":"S Wotton","year":"2008","unstructured":"Wotton S, Terry A, Kilbey A, Jenkins A, Herzyk P, Cameron E, et al. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene. 2008;27:5856\u201366.","journal-title":"Oncogene"},{"key":"810_CR50","doi-asserted-by":"crossref","unstructured":"Lopez-Millan B, Sanch\u00e9z-Mart\u00ednez D, Roca-Ho H, Guti\u00e9rrez-Ag\u00fcera F, Molina O, Diaz de la Guardia R, et al. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia. 2019;33:1557\u201369.","DOI":"10.1038\/s41375-018-0353-0"},{"key":"810_CR51","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.2023022050","volume":"144","author":"B Lopez-Millan","year":"2024","unstructured":"Lopez-Millan B, Rubio-Gayarre A, Vinyoles M, Trincado JL, Fraga MF, Fernandez-Fuentes N, et al. NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression. Blood. 2024;144:2002\u201317.","journal-title":"Blood"},{"key":"810_CR52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08301.x","volume":"150","author":"DA Moreno","year":"2010","unstructured":"Moreno DA, Scrideli CA, Cortez MAA, De Paula QR, Valera ET, Da Silva SV, et al. research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol. 2010;150:665\u201373.","journal-title":"Br J Haematol"},{"key":"810_CR53","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41419-020-02949-1","volume":"11","author":"Z Wang","year":"2020","unstructured":"Wang Z, Zhang Y, Zhu S, Peng H, Chen Y, Cheng Z, et al. A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7\/MEF2C interaction in BCR-ABL1\u2212 pre-B-ALL. Cell Death Dis. 2020;11:738.","journal-title":"Cell Death Dis"},{"key":"810_CR54","doi-asserted-by":"crossref","unstructured":"Verbeek TCAI, Vrenken KS, Arentsen-Peters STCJM, Castro PG, van de Ven M, van Tellingen O, et al. Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. Commun Biol. 2024;7:1257.","DOI":"10.1038\/s42003-024-06916-w"},{"key":"810_CR55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.molcel.2014.06.005","volume":"55","author":"EM Riising","year":"2014","unstructured":"Riising EM, Comet I, Leblanc B, Wu X, Johansen JV, Helin K. Gene Silencing Triggers Polycomb Repressive Complex 2 Recruitment to CpG Islands Genome Wide. Mol Cell. 2014;55:347\u201360.","journal-title":"Mol Cell"},{"key":"810_CR56","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vir\u00e9","year":"2006","unstructured":"Vir\u00e9 E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439:871\u20134.","journal-title":"Nature"},{"key":"810_CR57","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5483\/BMBRep.2022.55.12.174","volume":"55","author":"SH Lee","year":"2022","unstructured":"Lee SH, Li Y, Kim H, Eum S, Park K, Lee C-H. The role of EZH1 and EZH2 in development and cancer. BMB Rep. 2022;55:595\u2013601.","journal-title":"BMB Rep"},{"key":"810_CR58","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/blood.2020005037","volume":"136","author":"MM Dzama","year":"2020","unstructured":"Dzama MM, Steiner M, Rausch J, Sasca D, Sch\u00f6nfeld J, Kunz K, et al. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood. 2020;136:2442\u201356.","journal-title":"Blood"},{"key":"810_CR59","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1101\/gad.1741408","volume":"22","author":"MG Guenther","year":"2008","unstructured":"Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008;22:3403\u20138.","journal-title":"Genes Dev"},{"key":"810_CR60","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2016.10.008","volume":"30","author":"S Lin","year":"2016","unstructured":"Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, et al. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 2016;30:737\u201349.","journal-title":"Cancer Cell"},{"key":"810_CR61","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2015.03.012","volume":"27","author":"MWM K\u00fchn","year":"2015","unstructured":"K\u00fchn MWM, Armstrong SA. Designed to Kill: Novel Menin-MLL Inhibitors Target MLL -Rearranged Leukemia. Cancer Cell. 2015;27:431\u20133.","journal-title":"Cancer Cell"},{"key":"810_CR62","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","volume":"27","author":"D Borkin","year":"2015","unstructured":"Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, et al. Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo. Cancer Cell. 2015;27:589\u2013602.","journal-title":"Cancer Cell"},{"key":"810_CR63","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1182\/blood.2020006113","volume":"136","author":"F Perner","year":"2020","unstructured":"Perner F, Gadrey JY, Xiong Y, Hatton C, Eschle BK, Weiss A, et al. Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood. 2020;136:1983\u20138.","journal-title":"Blood"},{"key":"810_CR64","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35:2482\u201395.","journal-title":"Leukemia"},{"key":"810_CR65","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020;130:981\u201397.","journal-title":"J Clin Invest"},{"key":"810_CR66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13148-019-0723-0","volume":"11","author":"J Ye","year":"2019","unstructured":"Ye J, Zha J, Shi Y, Li Y, Yuan D, Chen Q, et al. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Clin Epigenetics. 2019;11:137.","journal-title":"Clin Epigenetics"},{"key":"810_CR67","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"810_CR68","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615:913\u20139.","journal-title":"Nature"},{"key":"810_CR69","first-page":"1","volume":"100","author":"W Liao","year":"2021","unstructured":"Liao W, Kohler ME, Fry T, Ernst P. Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia Exp Hematol. 2021;100:1\u201311.","journal-title":"Lessons from MLL-r leukemia Exp Hematol"},{"key":"810_CR70","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi L-A, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406\u201310.","journal-title":"Blood"},{"key":"810_CR71","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/bloodadvances.2018018093","volume":"2","author":"M W\u00f6lfl","year":"2018","unstructured":"W\u00f6lfl M, Rasche M, Eyrich M, Schmid R, Reinhardt D, Schlegel PG. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL. Blood Adv. 2018;2:1382\u20135.","journal-title":"Blood Adv"},{"key":"810_CR72","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","volume":"7","author":"AJ Lamble","year":"2023","unstructured":"Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, et al. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023;7:575\u201385.","journal-title":"Blood Adv"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00810-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:25:39Z","timestamp":1757309139000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00810-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00810-1","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental work proposed in this study involving primary human samples has been approved by the IRB board at Germans Trias i Pujol hospital, at Can Ruti Campus in Badalona (approval code: PI21\/01451). Patient samples from KMT2A germline and t(4;11) pro-B-ALL were obtained with the authorization from patients\u2019 legal representatives. All animal procedures involved are approved by the Animal Research Ethics Committee of CMCiB-IGTP facility (20\u2013004-JRU-P5) and the Animal Research Commission from the Government of Catalonia (CEA\/10473_MR2\/P5).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All contributing authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PM is cofounder of OneChain Immunotherapeutics, a spin-off company focused on CAR-T cells with no connection with the present work. The rest of the authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}